Recursion plans to present updated data from the TUPELO trial in an upcoming webinar scheduled for December 8, 2025. This presentation will provide further insights into the drug’s safety and efficacy ...
Hosted on MSN
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback